Table 4.
Summary of therapeutic trials combining targeted therapy – chemotherapy – immunotherapy in colorectal cancers. This is a non-exhaustive list from the ClinicalTrial.gov website (NCT identifier). CRC: Colorectal Cancer, aPD-1: anti programmed cell death protein 1, VEGF(R)i: Vascular Endothelial Growth Factor (receptor) inhibitor, MSI: Microsatellite Instability, COXi: Cyclo-Oxygenase-2 Inhibitor, aPD-L1: anti programmed death ligand 1, HDACi: Histone De-Acetylase Inhibitor, TKi: Tyrosine Kinase inhibitor, BRAFi: B-raf inhibitor, EGFRi: Epidermal Growth Factor Receptor inhibitor, PI3Ki: Phosphatidylinositol 3-kinase inhibitor, BTKi: Bruton’s Tyrosine Kinase (BTK) inhibitors, aCTLA-4: anti Cytotoxic T-lymphocyte antigen 4, MEKi: MAPK-ERK inhibitor.
| NCT identifier | Phase | Tumor type | Immunotherapies | Targeted therapies | Chemotherapies |
|---|---|---|---|---|---|
| NCT02298959 | I | Advanced CRC | Pembrolizumab (aPD-1) |
Ziv-aflibercept (VEGF-trap) |
None |
| NCT03926338 | I/II | Resectable CRC MSI |
Toripalimab (aPD-1) |
Celecoxib (COXi) | None |
| NCT03555149 | I/II | Advanced CRC | Atezolizumab (aPD-L1) |
Bevacizumab (VEGFi) Regorafenib (multiple TKi) Isatuximab (HDACi) AB928 (Dual Adenosine Receptor Antagonist |
None |
| NCT04110093 | I/II | Advanced CRC | Camrelizumab Nivolumab Sintilimab Toripalimab (aPD-1) |
Regorafenib (multiple TKi) |
None |
| NCT04017650 | I/II | Advanced CRC | Nivolumab (aPD-1) |
Encorafenib (BRAFi) Cetuximab (EGFRi) |
None |
| NCT03711058 | I/II | Advanced CRC | Nivolumab (aPD-1) |
Copanlisib (PI3Ki) |
None |
| NCT03332498 | I/II | Advanced CRC | Pembrolizumab (aPD-1) |
Ibrutinib (BTKi) |
None |
| NCT03377361 | I/II | Advanced CRC | Nivolumab (aPD-1) Ipilimumab (aCTLA-4) |
Trametinib (MEKi) |
None |
| NCT04715633 | II | Resectable CRC MSI |
Camrelizumab (aPD-1) |
Apatinib (VEGFRi) |
None |
| NCT04745130 | II | Advanced CRC | Sintilimab (aPD-1) |
Regorafenib (multiple TKi) Cetuximab (EGFRi) |
None |
| NCT04866862 | II | Advanced CRC | Camrelizumab (aPD-1) |
Fruquintinib (VEGFRi) |
None |
| NCT03608046 | II | Advanced CRC | Avelumab (aPD-L1) |
Cetuximab (EGFRi) |
Irinotecan |
| NCT04271813 | II | Advanced CRC | Sintilimab (aPD-L1) |
Anlotinib (VEGFRi) |
None |
| NCT04527068 | II | Advanced CRC | Tripleitriumab (aPD-1) |
Bevacizumab (VEGFi) |
None |
| NCT04262687 | II | Advanced CRC | Pembrolizumab (aPD-1) |
Bevacizumab (VEGFi) |
Oxaliplatin Capecitabine |
| NCT02997228 | III | Advanced CRC | Atezolizumab (aPD-L1) |
Bevacizumab (VEGFi) |
Oxaliplatin Fluorouracil |